VRDN / Viridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease

Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate more_horizontal

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.26. This comp more_horizontal

There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroi more_horizontal

Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its s more_horizontal

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scot more_horizontal

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $1. This compare more_horizontal

Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again. more_horizontal

Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q4 2022 Earnings Conference Call March 8, 2023 8:00 PM ET Company Participants Louisa Stone - Manager, Inve more_horizontal